Skip to main content

Table 1 Summary of chemoprophylaxis study design features

From: Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations

Trial characteristics Number of trials (%), n = 76 Number proposed to be enrolled (%); total, 208,367 Median (IQR)
Design and intervention Randomisation
 Randomised Total 63(83) 197,010 (95) 600 (236–1834)
Cluster randomised 8(11) 12,710 (6) 1575 (1050–2075)
 Non-randomised 13 (17) 11,357 (5) 400 (300–1000)
Approach
 PrEP 55(72) 180,848 (87) 440 (203–1500)
 PEP 21(28) 27,519 (13) 1000 (400–2000)
Blinding
 Single-blinded 10 (13)   
 Double-blinded 36(47)
 Open-label 28 (37)
 Not stated 2 (3)
Estimated sample size (N)
 ≤ 299 18 (24)   
 300–499 20(26)
 500–999 7 (9)
 1000–4999 26 (34)
 5000+ 5 (7)
Agent
 “Western” pharmaceutical agents 67 (88)   
 TCM/ayurvedic 9(12)
Population HCW 49 (64) 160,398 (77) 450 (350–1212)
Close contacts of COVID-19 patients 11 (14) 11,326 (5) 600 (293–1410)
Both HCW and close contacts 5 (7) 9625 (5) 2000 (1739–2486)
Older adults (65+ years) 3 (4) 2736 (1) 600 (403–1265)
General population 2 (3) 22,000 (11) 11,000 (6500–15,500)
Children (1–18 years) 1 (1) 200 (<1) N/A
Other/unspecified (includes cancer, transplant and haemodialysis patients, cardiovascular/respiratory co-morbidities) 5 (7) 2132 (1) 200 (132–200)
  1. Also includes variants reporting higher levels of blinding